2 The technology

2 The technology

Nivolumab (Opdivo, Bristol-Myers Squibb)

Marketing authorisation

Nivolumab has a marketing authorisation in the UK as monotherapy for 'the treatment of squamous cell cancer of the head and neck in adults progressing on or after platinum-based therapy'.

Recommended dose and schedule

3 mg/kg every 2 weeks by intravenous infusion over 60 minutes.


£439 per 40 mg vial and £1,097 per 100 mg vial (excluding VAT; British national formulary [BNF] online, [accessed December 2016] and company submission).

As part of the managed access agreement, the company (Bristol-Myers Squibb) has a commercial access agreement with NHS England. This makes nivolumab available at a reduced cost. The financial terms of the agreement are commercial in confidence.

  • National Institute for Health and Care Excellence (NICE)